CTRI/2023/10/058501招募中Unknown
A randomized, double-blind, parallel group clinical study to evaluate efficacy and safety of UO ABG 01 in the management of borderline cardio vascular risk factors - NI
Xtractiva Life Science Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female subjects between 25 to 65 years of age
- •Ability to understand the risks/benefits of the protocol
- •Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of non-childbearing potential must be amenorrheic for at least 1 years or had a hysterectomy and/or bilateral oophorectomy
- •Serum triglycerides > 115mg/dL and less than < 199 mg/dL
- •If former smoker (previously smoked =10 cigarettes/day for at least 1 year, cessation for at least 6 months
- •Willing to give written informed consent and willing to comply with trial protocol
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitisEosinophilic oesophagitisEUCTR2005-006074-10-GBGlaxoSmithKline Research & Development Ltd.72
招募中
3 期
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant AlbendazoleOnchocerciasisPACTR202003567524647Medicines Development for Global Health12,500
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel-Group Clinical Research Study to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care in comparison to Placebo Added to Standard of Care, in Non-Alcoholic Fatty Liver Disease (NAFLD) Connected with Type 2 Diabetes Mellitus (T2DM) and/or abnormally high levels of fats (lipids) in the blood (Hyperlipidemia) and/or abnormal accumulation of body fat (Obesity)on-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesityMedDRA version: 25.0Level: LLTClassification code 10082249Term: Nonalcoholic fatty liver diseaseSystem Organ Class: 100000004871EUCTR2021-006069-39-DESanofi-Aventis Recherche & Développement190
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel-Group Clinical Research Study to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care in comparison to Placebo Added to Standard of Care, in Non-Alcoholic Fatty Liver Disease (NAFLD) Connected with Type 2 Diabetes Mellitus (T2DM) and/or abnormally high levels of fats (lipids) in the blood (Hyperlipidemia) and/or abnormal accumulation of body fat (Obesity)on-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesityMedDRA version: 25.0Level: LLTClassification code 10082249Term: Nonalcoholic fatty liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-006069-39-PLSanofi-Aventis Recherche & Développement190
尚未招募
不适用
A Clinical Study to Evaluate the Efficacy and Safety of Viwithan in stressed Adult healthy Humans.CTRI/2022/12/048354Vidya Herbs Pvt Ltd